Ultrasound-based nanomedicine for molecular imaging of prostate cancer: from diagnostics to theranostics

References

• 1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J. Clin. 71(1), 7–33 (2021).
  MedlineGoogle Scholar
• 2. Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
  MedlineGoogle Scholar
• 3. Andreoiu M, Cheng L. Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum. Pathol. 41(6), 781–793 (2010).
  MedlineGoogle Scholar
• 4. Priester A, Natarajan S, Khoshnoodi P et al. Magnetic resonance imaging underestimation of prostate cancer geometry: use of patient specific molds to correlate images with whole mount pathology. J. Urol. 197(2), 320–326 (2017).
  MedlineGoogle Scholar
• 5. Mottet N, van den Bergh RCN, Briers E et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur. Urol. 79(2), 243–262 (2021).
  Medline CASGoogle Scholar
• 6. Mohler JL, Antonarakis ES, Armstrong AJ et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 17(5), 479–505 (2019).
  Medline CASGoogle Scholar
• 7. Grey A, Ahmed HU. Multiparametric ultrasound in the diagnosis of prostate cancer. Curr. Opin. Urol. 26(1), 114–119 (2016).
  MedlineGoogle Scholar
• 8. Smeenge M, Tranquart F, Mannaerts CK et al. First-in-human ultrasound molecular imaging with a VEGFR2-specific ultrasound molecular contrast agent (BR55) in prostate cancer: a safety and feasibility pilot study. Invest. Radiol. 52(7), 419–427 (2017).
  Medline CASGoogle Scholar
• 9. Wu H, Rognin NG, Krupka TM et al. Acoustic characterization and pharmacokinetic analyses of new nanobubble ultrasound contrast agents. Ultrasound Med. Biol. 39(11), 2137–2146 (2013).
  MedlineGoogle Scholar
• 10. Zlitni A, Gambhir SS. Molecular imaging agents for ultrasound. Curr. Opin. Chem. Biol. 45, 113–120 (2018).
  Medline CASGoogle Scholar
• 11. Wischhusen J, Padilla F. Ultrasound-targeted microbubble destruction (UTMD) for localized drug delivery into tumor tissue. IRBM 40(1), 10–15 (2019).
  Google Scholar
• 12. Ding Y, Cao Q, Qian S et al. Optimized anti-prostate-specific membrane antigen single-chain variable fragment-loaded nanobubbles as a novel targeted ultrasound contrast agent for the diagnosis of prostate cancer. J. Ultrasound Med. 39(4), 761–773 (2020).
  MedlineGoogle Scholar
• 13. Perera RH, de Leon A, Wang X et al. Real time ultrasound molecular imaging of prostate cancer with PSMA-targeted nanobubbles. Nanomedicine 28, 102213 (2020).
  Medline CASGoogle Scholar
• 14. Zhao M, Zhu Y, Zhang Y et al. CDCP1-targeted nanoparticles encapsulating phase-shift perfluorohexan for molecular US imaging in vitro. Clin. Hemorheol. Microcirc. doi:10.3233/CH-200900 (2020) (Epub ahead of print).
  Google Scholar
• 15. Zhu Y, Sun Y, Liu W et al. Magnetic polymeric nanobubbles with optimized core size for MRI/ultrasound bimodal molecular imaging of prostate cancer. Nanomedicine (Lond.) 15(30), 2901–2916 (2020).
  CASGoogle Scholar
• 16. Wang Y, Lan M, Shen D et al. Targeted nanobubbles carrying indocyanine green for ultrasound, photoacoustic and fluorescence imaging of prostate cancer. Int. J. Nanomedicine 15, 4289–4309 (2020).
  Medline CASGoogle Scholar
• 17. Wu M, Wang Y, Wang Y et al. Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-co-glycolic acid) nanobubbles for ultrasound imaging and therapy of prostate cancer. Int. J. Nanomedicine 12, 5313–5330 (2017).
  Medline CASGoogle Scholar
• 18. Wu M, Zhao H, Guo L et al. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer. Drug Deliv. 25(1), 226–240 (2018).
  Medline CASGoogle Scholar
• 19. You Y, Liang X, Yin T et al. Porphyrin-grafted lipid microbubbles for the enhanced efficacy of photodynamic therapy in prostate cancer through ultrasound-controlled in situ accumulation. Theranostics 8(6), 1665–1677 (2018).
  Medline CASGoogle Scholar